Sign up to create alerts for Instruments,
Economic Events and content by followed authors
Free Sign Up Already have an account? Sign In
Chiaretto Calo
Nov 24, 2023 10:33AM ET
ESSA Pharma recently presented some impressive data at the European Society of Medical Oncology 2023 Congress. They've been working on this game-changing drug called masofaniten (previously known as EPI-7386), and the results are turning heads. Masofaniten is a novel androgen receptor inhibitor, a new kind of treatment for prostate cancer that works differently from anything else out there.
Prostate cancer is a major issue worldwide, reaching millions of people, and ESSA's approach is innovative. Their drug specifically targets the N-terminal domain of the androgen receptor, a pathway crucial in prostate cancer growth. What's more, this pathway hasn't been targeted by other therapies yet, which positions masofaniten as a potential first-in-class drug.
The data from their Phase 1/2 trials is what's really stirring up excitement. In these trials, masofaniten, combined with another drug called enzalutamide, showed deep and durable reductions in prostate-specific antigen (PSA) levels in patients. These reductions are a big indicator of the drug’s effectiveness against metastatic castration-resistant prostate cancer. And guess what? Most of the patients showed significant improvements.
The U.S. Food and Drug Administration has granted Fast Track designation to masofaniten for this specific cancer treatment. Plus, ESSA retains all rights to masofaniten globally, which is huge for its valuation and potential profits.
1
0